The selected target: $100 per share, a round-number psychological milestone roughly 56% above recent trading levels. Strongest bullish factor: Accelerating adoption of the Atera platform, a 74% gross margin, and raised 2026 revenue guidance of $610–$630 million.

10x Genomics (TXG) shares climbed roughly 35.7% over the trailing 30 days, rising from a closing price of $47.05 to about $63.87. The advance was powered by a stronger-than-expected Q2 2026 report, an upward revision to full-year revenue guidance, and early enthusiasm for the new Atera spatial biology platform.

WEAV shares climbed +31.83% to $7.29 during regular trading, versus a prior-session close of $5.53. The intraday surge followed Weave's announcement of a definitive agreement to be acquired by Francisco Partners.

HeartFlow shares rose about 54.4% in the 30 days through the August 14, 2026 close, from $27.25 on July 15 to $42.08. The advance was led by second-quarter results: revenue of $64.1 million, up roughly 48% year over year, and an adjusted loss of $0.07 per share that beat consensus expectations for a wider loss.

HeartFlow shares are up +25.64% in regular trading Friday at $38.96, versus the prior close of $31.01. The move extends an after-hours surge following Q2 results: revenue rose +48% year-over-year to $64.1 million, beating forecasts, and adjusted loss per share of -$0.07 was much narrower than expected.

Waystar shares have gained approximately 8% over the last 30 days, rebounding from a mid-July dip and climbing above the $24 level following strong second-quarter results. Q2 2026 revenue reached $320 million, up 18% year-over-year, while adjusted EBITDA of $137 million exceeded Wall Street expectations.

Price target: $60 per share — representing roughly 15% upside from TXG's last close of $52.03, and aligning with the high end of recently raised analyst forecasts. Strongest bullish factor: The launch of the Atera spatial biology platform has generated extraordinary early demand, with booked orders already exceeding manufacturing capacity for 2026.

CERT closed at $7.80 on Tuesday, down -4.65% from $8.18, after an extreme intraday swing from a low of $6.33 to a high of $7.83 on heavy volume of 10.8M shares. The move followed a steep premarket gap down of nearly -19% after Q2 2026 earnings were released before the open, with the stock recovering substantially during the regular session.

WAY plunged -16.03% during regular trading on July 30, extending an after-hours drop of -5.38% that began following its Q2 2026 earnings release after the July 29 close. The selloff came despite a headline beat — EPS of $0.43 vs. $0.40 expected and revenue of $319.7M vs. $316.2M — and raised full-year 2026 guidance for both revenue and adjusted EBITDA.

TDOC plunged approximately -27.2% during the regular session on Thursday, extending a sharp after-hours selloff that began Wednesday evening following its Q2 2026 earnings release. The primary catalyst: Q2 revenue of $606.9 million missed Wall Street's $615.4 million consensus, while BetterHelp segment sales dropped -12% year-over-year amid accelerating cash-pay customer erosion.

Tempus AI shares fell approximately 28.7% over the past 30 days, dropping from $58.31 on June 29 to $41.55 on July 29, 2026. The steep decline was triggered by the announcement of a $1.5 billion all-stock acquisition of Personalis, which raised integration and dilution concerns among investors.

EVH plunged -13.64% during regular trading Thursday, dropping from a prior close of $5.57 to an intraday low near $4.81, marking its steepest single-day decline in months. Citigroup analyst Daniel Grosslight downgraded Evolent Health from Buy to Sell, citing a less favorable risk/reward after the stock rallied more than +100% over the prior three months.

TEM shares tumbled -8.94% during Monday's regular session, falling from Friday's close of $52.47 to approximately $47.78, after opening sharply lower following premarket weakness. The primary catalyst is Tempus AI's announcement that it will acquire cancer-test maker Personalis (PSNL) in an all-stock deal valued at $1.5 billion, at $16.25 per share — a transaction viewed by investors as dilutive and costly for a company still reporting net losses.

Hinge Health (HNGE) shares surged approximately 30.7% over the last 30 days, climbing from $68.35 on June 15, 2026, to $89.31 by July 14, 2026. The rally was fueled by a series of analyst price-target upgrades, bullish Q2 user-engagement data, and growing confidence in the company's AI-driven margin expansion story.

10x Genomics shares surged roughly 44% over the past 30 days, climbing from approximately $28.84 to $41.60 and repeatedly touching new 52-week highs. The rally was fueled by a series of catalysts including the acquisition of Proteintech Genomics, a multi-year research partnership with Cleveland Clinic, and a wave of analyst price target increases.

HTFL shares tumbled -14.25% during Tuesday's regular session, falling from Friday's close of $35.65 to $30.57, as heavy selling pressure continued following the June 26 disclosure of CEO John Farquhar's $1.36 million insider stock sale. The CEO sold 38,900 shares at $35.00 on June 24 under a pre-arranged Rule 10b5-1 trading plan, a move that rattled investor confidence and triggered a sharp reassessment of the company's near-term prospects.

Simulations Plus (SLP) surged approximately 29% over the last 30 days, climbing from $14.10 on May 19 to $18.24 by June 18, 2026. The definitive acquisition agreement with Altaris for $18.50 per share in cash, announced in mid-June, served as the primary catalyst for the sharp upward move.

Veeva Systems reported total revenue of $882.9 million for the fiscal 2027 first quarter ended April 30, 2026, representing 16% year-over-year growth. Subscription services revenue reached $730.2 million, up 15% from the prior year.

Veeva Systems is scheduled to report fiscal 2027 first-quarter results on June 3, 2026. The company provided revenue guidance of $855 million to $858 million for the quarter.

Tempus AI reported Q1 2026 revenue growth of 36% year-over-year to $348.1 million, driven by diagnostics and data applications. Company raised full-year 2026 revenue guidance to $1.59–$1.60 billion, targeting ~$65 million in adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization).